Alzinova
Alzinova: Another external validation (Redeye)

2021-01-15 08:30
Redeye comments on the news earlier this week that an Eli Lilly amyloid-beta (Aβ)-asset, donanemab, slowed cognitive decline in a phase 2 study. There are now several drug candidates targeting Aβ that has shown efficacy signals. It provides a validation of the Aβ hypothesis generally and for Alzinova's vaccine approach specifically.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Alzinova - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -